Your browser doesn't support javascript.
loading
Contact Tracing and Exposure Investigation in Response to the First Case of Monkeypox Virus Infection in the United States During the 2022 Global Monkeypox Outbreak.
Shenoy, Erica S; Wright, Sharon B; Barbeau, Deborah N; Foster, Lisa A; King, Aleah D; Gordon, Patrick S; Mehrotra, Preeti; Pepe, Dana E; Caroff, Daniel A; Kim, Lindsey R; McGrath, Shannon E; Courtney, Amy; Fahy, Meredith; Hooper, David C; Macdonald, Kaitlin; Searle, Eileen F; Shearer, Jennifer A; Zachary, Kimon C; Bouton, Lindsay; Cumming, Melissa; Hopkins, Brandi; Jacoboski, Juliana; Mann, Erin; Osborne, Matthew; Perez, Carley; Schultz, Jordan; Scotland, Sarah; Traphagen, Elizabeth; Madoff, Lawrence C; Brown, Catherine M.
Afiliación
  • Shenoy ES; Harvard Medical School and Regional Emerging Special Pathogens Treatment Center, Infection Control Unit, and Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts (E.S.S., K.C.Z.).
  • Wright SB; Harvard Medical School and Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, and Division of Infection Prevention and Control, Beth Israel Lahey Health, Cambridge, Massachusetts (S.B.W.).
  • Barbeau DN; Harvard T. H. Chan School of Public Health and Employee Health Management, Beth Israel Deaconess Medical Center, Boston, and Occupational and Environmental Health Network, Marlborough, Massachusetts (D.N.B.).
  • Foster LA; Employee Health Department, Beth Israel Lahey Health, Burlington, Massachusetts (L.A.F.).
  • King AD; Division of Infection Prevention and Control, Beth Israel Lahey Health, Cambridge, Massachusetts (A.D.K.).
  • Gordon PS; Division of Infection Control/Hospital Epidemiology, Silverman Institute for Health Care Quality and Safety, Beth Israel Deaconess Medical Center, Boston, Massachusetts (P.S.G.).
  • Mehrotra P; Harvard Medical School, Division of Infectious Diseases, Beth Israel Deaconess Medical Center, and Division of Infection Control/Hospital Epidemiology, Silverman Institute for Health Care Quality and Safety, Beth Israel Deaconess Medical Center, Boston, Massachusetts (P.M., D.E.P.).
  • Pepe DE; Harvard Medical School, Division of Infectious Diseases, Beth Israel Deaconess Medical Center, and Division of Infection Control/Hospital Epidemiology, Silverman Institute for Health Care Quality and Safety, Beth Israel Deaconess Medical Center, Boston, Massachusetts (P.M., D.E.P.).
  • Caroff DA; Tufts University School of Medicine, Boston, and Division of Hospital Epidemiology and Infection Prevention and Division of Infectious Diseases, Lahey Hospital and Medical Center, Burlington, Massachusetts (D.A.C.).
  • Kim LR; Division of Hospital Epidemiology and Infection Prevention, Lahey Hospital and Medical Center, Burlington, Massachusetts (L.R.K., S.E.M.).
  • McGrath SE; Division of Hospital Epidemiology and Infection Prevention, Lahey Hospital and Medical Center, Burlington, Massachusetts (L.R.K., S.E.M.).
  • Courtney A; Infection Control Unit, Massachusetts General Hospital, Boston, Massachusetts (A.C.).
  • Fahy M; Regional Emerging Special Pathogens Treatment Center and Infection Control Unit, Massachusetts General Hospital, Boston, Massachusetts (M.F.).
  • Hooper DC; Harvard Medical School, Infection Control Unit and Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts (D.C.H.).
  • Macdonald K; Occupational Health Services, Mass General Brigham, Boston, Massachusetts (K.M.).
  • Searle EF; Regional Emerging Special Pathogens Treatment Center and Center for Disaster Medicine, Massachusetts General Hospital, Boston, Massachusetts (E.F.S.).
  • Shearer JA; Center for Disaster Medicine, Massachusetts General Hospital, and Department of Emergency Preparedness and Business Continuity, Mass General Brigham, Boston, Massachusetts (J.A.S.).
  • Zachary KC; Harvard Medical School and Regional Emerging Special Pathogens Treatment Center, Infection Control Unit, and Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts (E.S.S., K.C.Z.).
  • Bouton L; Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts (L.B., M.C., B.H., J.J., E.M., M.O., C.P., J.S., S.S., E.T., C.M.B.).
  • Cumming M; Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts (L.B., M.C., B.H., J.J., E.M., M.O., C.P., J.S., S.S., E.T., C.M.B.).
  • Hopkins B; Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts (L.B., M.C., B.H., J.J., E.M., M.O., C.P., J.S., S.S., E.T., C.M.B.).
  • Jacoboski J; Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts (L.B., M.C., B.H., J.J., E.M., M.O., C.P., J.S., S.S., E.T., C.M.B.).
  • Mann E; Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts (L.B., M.C., B.H., J.J., E.M., M.O., C.P., J.S., S.S., E.T., C.M.B.).
  • Osborne M; Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts (L.B., M.C., B.H., J.J., E.M., M.O., C.P., J.S., S.S., E.T., C.M.B.).
  • Perez C; Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts (L.B., M.C., B.H., J.J., E.M., M.O., C.P., J.S., S.S., E.T., C.M.B.).
  • Schultz J; Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts (L.B., M.C., B.H., J.J., E.M., M.O., C.P., J.S., S.S., E.T., C.M.B.).
  • Scotland S; Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts (L.B., M.C., B.H., J.J., E.M., M.O., C.P., J.S., S.S., E.T., C.M.B.).
  • Traphagen E; Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts (L.B., M.C., B.H., J.J., E.M., M.O., C.P., J.S., S.S., E.T., C.M.B.).
  • Madoff LC; Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, and Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts (L.C.M.).
  • Brown CM; Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts (L.B., M.C., B.H., J.J., E.M., M.O., C.P., J.S., S.S., E.T., C.M.B.).
Ann Intern Med ; 175(12): 1639-1647, 2022 12.
Article en En | MEDLINE | ID: mdl-36343347
ABSTRACT

BACKGROUND:

In May 2022, the first case of monkeypox virus (MPXV) infection in the United States in the current global outbreak was identified. As part of the public health and health care facility response, a contact tracing and exposure investigation was done.

OBJECTIVE:

To describe the contact tracing, exposure identification, risk stratification, administration of postexposure prophylaxis (PEP), and exposure period monitoring for contacts of the index patient, including evaluation of persons who developed symptoms possibly consistent with MPXV infection.

DESIGN:

Contact tracing and exposure investigation.

SETTING:

Multiple health care facilities and community settings in Massachusetts.

PARTICIPANTS:

Persons identified as contacts of the index patient. INTERVENTION Contact notification, risk stratification, and symptom monitoring; PEP administration in a subset of contacts. MEASUREMENTS Epidemiologic and clinical data collected through standard surveillance procedures at each facility and then aggregated and analyzed.

RESULTS:

There were 37 community and 129 health care contacts identified, with 4 at high risk, 49 at intermediate risk, and 113 at low or uncertain risk. Fifteen health care contacts developed symptoms during the monitoring period. Three met criteria for MPXV testing, with negative results. Two community contacts developed symptoms. Neither met criteria for MPXV testing, and neither showed disease progression consistent with monkeypox. Among 4 persons with high-risk exposures offered PEP, 3 elected to receive PEP. Among 10 HCP with intermediate-risk exposures for which PEP was offered as part of informed clinical decision making, 2 elected to receive PEP. No transmissions were identified at the conclusion of the 21-day monitoring period, despite the delay in recognition of monkeypox in the index patient.

LIMITATION:

Descriptions of exposures are subject to recall bias, which affects risk stratification.

CONCLUSION:

In a contact tracing investigation involving 166 community and health care contacts of a patient with monkeypox, no secondary cases were identified. PRIMARY FUNDING SOURCE None.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mpox Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Ann Intern Med Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mpox Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Ann Intern Med Año: 2022 Tipo del documento: Article